EP Patent

EP4458825A1 — Salt of aminopyrimidine compound and use thereof

Assigned to Sunshine Lake Pharma Co Ltd · Expires 2024-11-06 · 2y expired

What this patent protects

Provided are a salt of an aminopyrimidine compound and a use thereof. Specifically, provided are a salt of ( S )-2-(1-((6-amino-5-(3-methyl-1,2,4-oxadiazol-5-yl)pyrimidin-4-yl)amino)ethyl)-5-(3-hydroxypro p-1-yn-1-yl)-3-phenylquinazolin-4(3 H )-one and a pharmaceutical compositio…

USPTO Abstract

Provided are a salt of an aminopyrimidine compound and a use thereof. Specifically, provided are a salt of ( S )-2-(1-((6-amino-5-(3-methyl-1,2,4-oxadiazol-5-yl)pyrimidin-4-yl)amino)ethyl)-5-(3-hydroxypro p-1-yn-1-yl)-3-phenylquinazolin-4(3 H )-one and a pharmaceutical composition comprising the salt. Further provided is a use thereof in the preparation of a medicament for treating and preventing diseases related to PI3K kinase abnormalities.

Drugs covered by this patent

Patent Metadata

Patent number
EP4458825A1
Jurisdiction
EP
Classification
Expires
2024-11-06
Drug substance claim
No
Drug product claim
No
Assignee
Sunshine Lake Pharma Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.